ERBB2 and bladder transitional cell carcinoma: Future studies integrating our model with drug‐specific biomarkers such as HER2 and HSPA1A may enable more accurate identification of patients likely to benefit from ADC‐based therapies, thereby contributing to precision medicine in BLCA.